PriceTargets.com logo

Longboard Pharmaceuticals - LBPH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $59.56
  • Forecasted Upside: -0.71%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$59.98 As of 12/2/2024 09:00 PM ET
▲ +0.02 (0.03%)

This chart shows the closing price for LBPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Longboard Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LBPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LBPH

Analyst Price Target is $59.56
▼ -0.71% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Longboard Pharmaceuticals in the last 3 months. The average price target is $59.56, with a high forecast of $90.00 and a low forecast of $32.00. The average price target represents a -0.71% upside from the last price of $59.98.

This chart shows the closing price for LBPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Longboard Pharmaceuticals. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/15/2024HC WainwrightReiterated RatingBuy ➝ Neutral$80.00 ➝ $60.00
10/15/2024Truist FinancialReiterated RatingBuy ➝ Hold$60.00 ➝ $60.00
10/14/2024WedbushDowngradeStrong-Buy ➝ Hold
10/14/2024B. RileyReiterated RatingBuy ➝ Neutral$45.00 ➝ $60.00
10/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral
9/18/2024HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $80.00
9/17/2024WedbushBoost TargetOutperform ➝ Outperform$40.00 ➝ $44.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00
9/10/2024Truist FinancialInitiated CoverageBuy$60.00
8/26/2024Evercore ISIReiterated RatingOutperform ➝ Outperform$80.00 ➝ $80.00
8/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
8/5/2024B. RileyBoost TargetBuy ➝ Buy$36.00 ➝ $45.00
8/2/2024CitigroupBoost TargetBuy ➝ Buy$45.00 ➝ $50.00
8/2/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00
8/2/2024WedbushLower TargetOutperform ➝ Outperform$42.00 ➝ $40.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
7/11/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$36.00 ➝ $60.00
7/2/2024CitigroupBoost TargetBuy ➝ Buy$40.00 ➝ $45.00
7/2/2024Evercore ISIBoost TargetOutperform ➝ Outperform$57.00 ➝ $80.00
7/1/2024Cantor FitzgeraldBoost TargetOverweight$60.00 ➝ $90.00
6/20/2024Evercore ISIBoost TargetOutperform ➝ Outperform$44.00 ➝ $57.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$60.00 ➝ $60.00
6/11/2024B. RileyBoost TargetBuy ➝ Buy$30.00 ➝ $36.00
6/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00
5/3/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$60.00
5/3/2024WedbushBoost TargetOutperform ➝ Outperform$32.00 ➝ $34.00
5/1/2024Robert W. BairdInitiated CoverageOutperform$36.00
4/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$60.00
3/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$60.00
3/13/2024WedbushReiterated RatingOutperform ➝ Outperform$32.00
3/13/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$60.00
2/16/2024CitigroupInitiated CoverageBuy$40.00
1/16/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$55.00 ➝ $60.00
1/8/2024HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $60.00
1/2/2024GuggenheimBoost TargetBuy ➝ Buy$16.00 ➝ $32.00
1/2/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$35.00 ➝ $55.00
12/19/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$35.00
10/24/2023Cantor FitzgeraldReiterated RatingOverweight$16.00 ➝ $35.00
10/12/2023WedbushReiterated RatingOutperform ➝ Outperform$11.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$16.00
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00
5/11/2023Cantor FitzgeraldBoost Target$11.00 ➝ $16.00
4/26/2023B. RileyInitiated CoverageBuy$13.00
3/15/2023HC WainwrightReiterated RatingBuy$25.00
3/5/2023CitigroupLower TargetBuy$24.00 ➝ $17.00
3/3/2023WedbushReiterated RatingOutperform
11/11/2022GuggenheimLower TargetBuy$18.00 ➝ $16.00
4/27/2022HC WainwrightInitiated CoverageBuy
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
2/14/2022WedbushInitiated CoverageOutperform$14.00
4/6/2021Evercore ISIInitiated CoverageOutperform$35.00
4/6/2021CitigroupInitiated CoverageBuy
4/6/2021Cantor FitzgeraldInitiated CoverageOverweight$32.00
4/6/2021GuggenheimInitiated CoverageBuy$27.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.10 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 9 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 13 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 14 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Longboard Pharmaceuticals logo
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Read More

Today's Range

Now: $59.98
Low: $59.98
High: $60.03

50 Day Range

MA: $59.75
Low: $58.99
High: $59.98

52 Week Range

Now: $59.98
Low: $3.60
High: $60.03

Volume

655,700 shs

Average Volume

1,113,743 shs

Market Capitalization

$2.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1

Frequently Asked Questions

What sell-side analysts currently cover shares of Longboard Pharmaceuticals?

The following equities research analysts have issued reports on Longboard Pharmaceuticals in the last year: B. Riley, Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, Robert W. Baird, Truist Financial Co., and Wedbush.
View the latest analyst ratings for LBPH.

What is the current price target for Longboard Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Longboard Pharmaceuticals in the last year. Their average twelve-month price target is $59.56, suggesting a possible downside of 0.7%. Cantor Fitzgerald has the highest price target set, predicting LBPH will reach $90.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $32.00 for Longboard Pharmaceuticals in the next year.
View the latest price targets for LBPH.

What is the current consensus analyst rating for Longboard Pharmaceuticals?

Longboard Pharmaceuticals currently has 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LBPH, but not buy more shares or sell existing shares.
View the latest ratings for LBPH.

What other companies compete with Longboard Pharmaceuticals?

Other companies that are similar to Longboard Pharmaceuticals include Intra-Cellular Therapies, Roivant Sciences, Ascendis Pharma A/S, Revolution Medicines and Lantheus. Learn More about companies similar to Longboard Pharmaceuticals.

How do I contact Longboard Pharmaceuticals' investor relations team?

Longboard Pharmaceuticals' physical mailing address is 6154 NANCY RIDGE DRIVE, SAN DIEGO CA, 92121. The company's listed phone number is 619-592-9775 and its investor relations email address is [email protected]. The official website for Longboard Pharmaceuticals is www.longboardpharma.com. Learn More about contacing Longboard Pharmaceuticals investor relations.